Analyst Ratings for NGM Biopharmaceuticals (NGM)
NGM Rating Summary
NGM Price Target Summary
- Highest: $9.00 (Cowen)
- Lowest: $4.00 (Goldman Sachs)
- Average: $5.83
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$5.83 (+12%)
* Over Last 12-Mos
Rating Score: 7 / 10
Percentile Rank: 75%
Avg. $ Target:
$5.83 (+12%)
* Over Last 12-Mos
Rating Score: 7 / 10
Percentile Rank: 75%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/18/2022 | Raymond James » Updated 11/4/2022 |
Steven Seedhouse | Downgrade | Outperform (Strong Buy) |
6.00 (4.00) |
11.55 (5.21) |
-54.89% | Details |
| 10/18/2022 | Goldman Sachs | Paul Choi | Downgrade | Neutral (Buy) |
4.00 (29.00) |
11.55 (5.21) |
-54.89% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
